EUCTR2005-004105-28-GR进行中（未招募）不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ S
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •1) Previous participation in an IVSR-UC visilizumab study.
- •2) Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Unable to understand the purpose and risks of the study, or unwilling or unable to provide signed and dated informed consent.
研究者
相似试验
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisIntravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-004105-28-NLPDL BioPharma, Inc300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-DEPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ SEUCTR2005-004105-28-FRPDL BioPharma, Inc.300
进行中（未招募）
不适用
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.EUCTR2005-004105-28-GBPDL BioPharma, Inc.300
进行中（未招募）
1 期
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.EUCTR2005-004105-28-IEPDL BioPharma, Inc.300